Clinical trials: LAM
HIV-1 Infection
Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
The primary objective of this study is to evaluate the efficacy of switching from a regimen of dolutegravir (DTG) and abacavir/lamivudine (ABC/3TC) or a fixed dose combination (FDC) of abacavir/dolutegravir/lamivudine…
- Trial name
- NCT02603120
- Testing
- ABC/DTG/3TC, B/F/TAF
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 567 people
- Sponsor
- Gilead Sciences
HIV Infections, AIDS-Associated Nephropathy
A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease
The purpose of this study is to compare the safety and effectiveness of saquinavir SGC plus stavudine (d4T) plus lamivudine (3TC) with that of saquinavir SGC plus nelfinavir plus d4T in patients with HIV-associated kidney…
- Trial name
- NCT00002397
- Testing
- Nelfinavir mesylate, Saquinavir, Lamivudine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
HIV-1-infection
REal-Life Cohort With DOlutegravir + LAmivudina
Since 1996, HAART based on 3-drug regimens (3DR) in people living with HIV (PLHIV) has decreased mortality and today, PLHIV have a life expectancy close to that of the general population.
- Trial name
- REDOLA (NCT04638686)
- Testing
- Dolutegravir 50 MG, Lamivudine 300 MG
- Where
- Spain
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Chronic Hepatitis B
Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents
Current treatment guidelines indicate that oral antiviral agents for HBeAg-positive chronic hepatitis B virus infection (CHB) can be stopped if the patient has undergone HBeAg seroconversion with HBV-DNA loss measured at two…
- Trial name
- NCT02337127
- Testing
- Lamivudine
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
HIV Infections
Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up
This is a phase 4, randomized, controlled, open-label, single-center clinical trial conducted at the Hospital de Infectología, National Medical Center "La Raza." The study employs a non-inferiority design with follow-up…
- Trial name
- TLACAELEL (NCT07138144)
- Testing
- Standard Medical Therapy, dual therapy
- Where
- Mexico
- Volunteers
- 156 people
- Sponsor
- José Antonio Mata Marín
Osteoarthritis, Knee
Autologous BMA vs Saline and LAM + LP-PRP vs Saline Evaluations in Knee OA
ABLE OA is a Health Canada authorized (phase II/III) trial [Parent Control #: 263591]. A multi-center, prospective, double-blinded, randomized, placebo-controlled adaptive trial to evaluate the efficacy of two minimally…
- Trial name
- ABLE-OA (NCT05517434)
- Testing
- Bone Marrow Aspirate (BMA): Minimally manipulated autologous cellular preparation, Lipoaspirate Micronized + Leukocyte-Poor Platelet-Rich Plasma (LAM + LP-PRP): Minimally manipulated autologous cellular preparations
- Where
- 2 sites in Canada
- Volunteers
- 148 people
- Sponsor
- University Health Network, Toronto
HIV Infections, Chronic Hepatitis B
Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection
This study will evaluate the safety and effectiveness of adefovir plus lamivudine for chronic hepatitis B infection in people with and without HIV infection.
- Trial name
- NCT00023153
- Testing
- Adefovir Dipivoxil
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
Apricitabine is a new NRTI which is active against drug-resistant HIV. NRTIs are often included as part of patients' treatment, but many HIV-infected patients develop resistance to commonly used NRTIs such as lamivudine (3TC) and…
- Trial name
- NCT00612898
- Testing
- apricitabine, lamivudine
- Where
- 100 sites in United States, Australia and 9 more
- Volunteers
- 239 people
- Sponsor
- Avexa
HIV Infections
A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP
This protocol aims to determine the risk/benefits of this policy by comparing head-to-head a regimen of GPO-VIR Z or TDF/FTC/NVP for 18 months in ARV-naïve patients to a 6-month lead in with GPO-VIR S followed by 12 months of…
- Trial name
- NCT00669487
- Testing
- AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
- Where
- Thailand
- Volunteers
- 150 people
- Sponsor
- SEARCH Research Foundation
Lymphangioleiomyomatosis
Discovery of Sirolimus Sensitive Biomarkers in Blood
Background: Lymphangioleiomyomatosis (LAM) is a rare, progressive disease. It usually affects women in the prime of their lives. It typically results in lung destruction.
- Trial name
- NCT03304678
- Testing
- Sirolimus 2mg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
AIDS
To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
To assess compliance of once daily dosing to assess their benefits in terms of potency and safety as well as their impact on adherence and quality of life.
- Trial name
- NCT00207168
- Testing
- Compliance
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Safety Study of Elvucitabine in HIV-1 Subjects
The purpose of this 28 day study is to assess the viral kinetics and safety of elvucitabine.
- Trial name
- NCT00405249
- Testing
- elvucitabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Thomas Jefferson University
Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that appears to behave like a slowly growing cancer. Since clinical progression is very slow, new blood tests have been used to speed the time required to find safe and…
- Trial name
- LAMP-2 (NCT06889168)
- Testing
- Imatimib Mesylate
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Columbia University
Hiv
DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)
The goal of this pilot, phase 2, single-arm, clinical trial is to assess the antiretroviral combination Doravirine (DOR)/Lamivudine (3TC)/Tenofovir Disproxyl Fumarate (TDF) in participants with suppressed HIV who previously…
- Trial name
- DOR (NCT06034938)
- Testing
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
- Where
- 4 sites in France
- Volunteers
- 32 people
- Sponsor
- University Hospital, Caen
Iron, Acute Myeloid Leukemia
Metabolism Des LAM
In this study, the investigators study the prognostic role of oxidative stress metabolism and iron in Acute myeloid leukemia.
- Conditions
- Iron, Acute Myeloid Leukemia, Diagnosis, Oxydative Stress
- Trial name
- LAM-ROS (NCT02176109)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Grenoble
Hepatitis B, Chronic
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
This study will evaluate the efficacy and safety of peginterferon alfa-2a or ADV, in participants with lamivudine-resistant HBeAg-positive chronic hepatitis B.
- Trial name
- NCT02598063
- Testing
- Adefovir dipivoxil, Lamivudine, Peginterferon alfa-2a
- Where
- 12 sites in China, Hong Kong
- Volunteers
- 255 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options
The purpose of this early access protocol is to provide access to adefovir dipivoxil prior to its commercial availability to people with lamivudine-resistant chronic hepatitis B who have limited treatment options.
- Trial name
- NCT00042393
- Testing
- Adefovir Dipivoxil
- Sponsor
- Gilead Sciences
HIV Infections
Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection
The purpose of this study is to compare the effectiveness, safety, and tolerability of 3 anti-HIV combination treatments that do not use protease inhibitors (PIs).
- Trial name
- NCT00013520
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Atazanavir, Lamivudine/Zidovudine
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 1,125 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
B/F/TAF to DTG/3TC Switch Study
OBJECTIVE: To assess the efficacy and safety of switch to dolutegravir and lamivudine (DTG/3TC) single tablet regimen from bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) in persons living with HIV aged 60 years…
- Trial name
- NCT06444620
- Testing
- DTG/3TC
- Where
- 2 sites in Kenya
- Volunteers
- 197 people
- Sponsor
- University of Nairobi
HIV Infections
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir [ABC] plus efavirenz [EFV] plus didanosine [ddI]) with and without hydroxyurea (HU).
- Trial name
- NCT00005018
- Testing
- Hydroxyurea, Abacavir sulfate, Efavirenz
- Where
- 23 sites in United States
- Volunteers
- 150 people
- Sponsor
- Glaxo Wellcome